Tool A T, Verhoeven A J
Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.
Arzneimittelforschung. 1995 Oct;45(10):1110-4.
Nimesulide (CAS 51803-78-2) has been shown to exert a marked anti-inflammatory effect in several in vivo models of inflammation. Recent studies indicate that nimesulide not only inhibits prostaglandin synthesis in certain cell types, but also has pleiotropic effects on neutrophil functions, including the respiratory burst, integrin-mediated adherence and synthesis of platelet-activating factor (PAF). In the present study, the effect of nimesulide on PAF synthesis was compared with its effect on the production of leukotriene B4 (LTB4). Nimesulide dose-dependently inhibited both processes in neutrophils stimulated by serum-treated zymosan (STZ) with a comparable efficacy (IC50 values between 10 and 20 mumol/l). In formyl-methionyl-leucyl-phenylalanine-stimulated neutrophils (treated with cytochalasin B), these IC50 values were 30 and 50 mumol/l for PAF and LTB4 synthesis, respectively. These results indicate an inhibition by nimesulide of a common step in the release of these lipid mediators, i.e. the activation of phospholipase A2, possibly by elevating intracellular cAMP. In support of this latter hypothesis, it was observed that nimesulide increased the level of cAMP almost 3-fold after STZ stimulation, whereas in fMLP-stimulated neutrophils these changes in cAMP levels were more dramatic. Furthermore, the inhibitory effects of nimesulide on PAF and LTB4 production could largely be prevented by addition of H89, an inhibitor of cAMP-dependent protein kinase (PK-A). It is concluded that an increase in intracellular cAMP is instrumental in the observed effects of nimesulide on the release of PAF and LTB4 by activated neutrophils and that limited availability of arachidonic acid, also the substrate for the cyclooxygenase pathway, may very well contribute to the effects of nimesulide on prostaglandin synthesis observed in other cell types.
尼美舒利(CAS 51803-78-2)已被证明在多种体内炎症模型中具有显著的抗炎作用。最近的研究表明,尼美舒利不仅能抑制某些细胞类型中前列腺素的合成,还对中性粒细胞功能具有多效性作用,包括呼吸爆发、整合素介导的黏附以及血小板活化因子(PAF)的合成。在本研究中,将尼美舒利对PAF合成的作用与其对白三烯B4(LTB4)产生的作用进行了比较。尼美舒利在剂量依赖性地抑制经血清处理的酵母聚糖(STZ)刺激的中性粒细胞中的这两个过程,其效力相当(IC50值在10至20 μmol/L之间)。在甲酰甲硫氨酰亮氨酰苯丙氨酸刺激的中性粒细胞(用细胞松弛素B处理)中,PAF和LTB4合成的这些IC50值分别为30和50 μmol/L。这些结果表明尼美舒利抑制了这些脂质介质释放中的一个共同步骤,即磷脂酶A2的激活,可能是通过提高细胞内cAMP水平来实现的。为支持后一种假设,观察到尼美舒利在STZ刺激后使cAMP水平增加了近3倍,而在fMLP刺激的中性粒细胞中,cAMP水平的这些变化更为显著。此外,加入cAMP依赖性蛋白激酶(PK-A)的抑制剂H89可在很大程度上防止尼美舒利对PAF和LTB4产生的抑制作用。得出的结论是,细胞内cAMP的增加有助于尼美舒利对活化中性粒细胞释放PAF和LTB4的观察到的作用,并且花生四烯酸(也是环氧化酶途径的底物)的有限可用性很可能促成了尼美舒利在其他细胞类型中观察到的对前列腺素合成的作用。